Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mihan Jafari Javid currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct art unit and 1 distinct examiner, indicating that the current prosecution activity is concentrated in one specialized review section. This focus allows the applicant to develop a targeted strategy that addresses the specific technical standards and legal interpretations of a single examiner group.
The busiest examiner for the portfolio is ARNOLD, ERNST V, who is responsible for 1 pending office action. Because this examiner is the only one assigned to the current pending workload, their individual review tendencies will be the primary factor in the prosecution outcome. Practitioners should review the examiner's history in the Biotechnology & Pharmaceuticals field to prepare for the specific requirements of this pending matter. Understanding the examiner's typical approach to claim rejections or evidence requirements can help in formulating a more effective response to the pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799901 | COMPOSITION AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DISORDERS, NEURODEGENERATIVE DISEASE AND NEUROPATHIC DISORDERS | ARNOLD, ERNST V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799901 | COMPOSITION AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DISORDERS, NEURODEGENERATIVE DISEASE AND NEUROPATHIC DISORDERS | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17799901 | COMPOSITION AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DISORDERS, NEURODEGENERATIVE DISEASE AND NEUROPATHIC DISORDERS | ARNOLD, ERNST V | 1600 | §103§112 | Final Rejection | — | Pending | Aug 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMihan Jafari Javid has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Ernst V Arnold has the most, with 1 of Mihan Jafari Javid's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.